Literature DB >> 19031027

Aspirin and the induction of tolerance by dendritic cells.

Matthew Buckland1, Giovanna Lombardi.   

Abstract

Tolerance is maintained by central and peripheral regulatory mechanisms and is essential to prevent autoimmunity. In the setting of solid organ or haematopoietic transplantation, the indirect pathway of allorecognition is a significant driver of chronic rejection. Chronic rejection proceeds despite effective immunosuppressive therapy, therefore achieving immunological tolerance to control the indirect pathway is a desirable goal. Tolerance induction may be achieved by vaccination with modified antigen presenting cells (APCs). Mature dendritic cells (DCs) are potent APCs, but immature DCs have been shown to have a reduced allo-stimulatory capacity and can be tolerogenic. Drug treatment has been shown to decrease the allo-stimulatory capacity of DC compared to immature DC. Dexamethasone and vitamin D3 have been established as having potent effects on dendritic cell immunogenicity.The effects of aspirin, a non-steroidal anti-inflammatory, on DCs have not previously been so extensively studied and here we will review the work which has been carried out using aspirin to induce tolerogenic DCs.We have examined the mechanisms of tolerance induction using human DCs and T cells. It has been possible to demonstrate that in aspirin treated, human DCs there is inhibition of the nuclear factor K-B (NFKB) signalling pathway, modified cytokine production, reduced expression of co-stimulatory molecules (CD40, CD80, and CD86) and increased expression of immunoglobulin-like transcript-3 (ILT3). The decreased expression of co-stimulatory molecules is maintained following cytokine or lipopolysaccharide (LPS) challenge. Drug treatment of DCs increases the expression of immunoglobulin-like transcript 3 (ILT3) when compared with immature DCs (iDCs), and these high levels of expression are maintained when the cells are challenged with a maturational stimulus. Aspirin also reduces the allo-stimulatory capacity of human DCs, and induces hypo-responsiveness and regulatory activity in responder T cells. These regulatory T-cells were CD4(+) CD25(+) FOXP3(+) and by studying CD25(-) or CD45RA populations, it was possible to determine that these regulatory T cells were generated de novo rather than requiring the expansion of naturally occurring Tregs. Aspirin continues therefore to be of interest with regard its wider effects on immune regulation, other than that mediated by direct inhibition of cyclo-oxygenase, in particular its ability to induce tolerogenic DCs at therapeutic concentrations in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19031027     DOI: 10.1007/978-3-540-71029-5_9

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  15 in total

Review 1.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease.

Authors:  Toshimasa Nakada
Journal:  Pediatr Cardiol       Date:  2014-08-27       Impact factor: 1.655

Review 3.  Immunotherapy with myeloid cells for tolerance induction.

Authors:  Mercedes Rodriguez-García; Peter Boros; Jonathan S Bromberg; Jordi C Ochando
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

4.  Central role of TRAF-interacting protein in a new model of brain sexual differentiation.

Authors:  Sudha Krishnan; Karlie A Intlekofer; Leah K Aggison; Sandra L Petersen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

5.  Expression of complement components, receptors and regulators by human dendritic cells.

Authors:  Ke Li; Henrieta Fazekasova; Naiyin Wang; Pervinder Sagoo; Qi Peng; Wafa Khamri; Chantelle Gomes; Steven H Sacks; Giovanna Lombardi; Wuding Zhou
Journal:  Mol Immunol       Date:  2011-03-23       Impact factor: 4.407

Review 6.  Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?

Authors:  Brett Phillips; Massimo Trucco; Nick Giannoukakis
Journal:  Clin Dev Immunol       Date:  2011-07-18

7.  In situ induction of dendritic cell-based T cell tolerance in humanized mice and nonhuman primates.

Authors:  Kyeong Cheon Jung; Chung-Gyu Park; Yoon Kyung Jeon; Hyo Jin Park; Young Larn Ban; Hye Sook Min; Eun Ji Kim; Ju Hyun Kim; Byung Hyun Kang; Seung Pyo Park; Youngmee Bae; Il-Hee Yoon; Yong-Hee Kim; Jae-Il Lee; Jung-Sik Kim; Jun-Seop Shin; Jaeseok Yang; Sung Joo Kim; Emily Rostlund; William A Muller; Seong Hoe Park
Journal:  J Exp Med       Date:  2011-10-24       Impact factor: 14.307

8.  GRAS-microparticle microarrays identify dendritic cell tolerogenic marker-inducing formulations.

Authors:  Matthew R Carstens; Clive H Wasserfall; Abhinav P Acharya; Jamal Lewis; Nikunj Agrawal; Kevin Koenders; Evelyn Bracho-Sanchez; Benjamin G Keselowsky
Journal:  Lab Chip       Date:  2021-09-14       Impact factor: 7.517

9.  Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.

Authors:  Joseph A Dottino; Qian Zhang; David S Loose; Bryan Fellman; Brenda D Melendez; Mikayla S Borthwick; Laurie J McKenzie; Ying Yuan; Richard K Yang; Russell R Broaddus; Karen H Lu; Pamela T Soliman; Melinda S Yates
Journal:  Am J Obstet Gynecol       Date:  2020-08-21       Impact factor: 8.661

10.  Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells.

Authors:  Tatjana Nikolic; Bart O Roep
Journal:  Front Immunol       Date:  2013-05-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.